Which contingent sequential screening protocol?
Explore the source record for details and available documents.
Biomarkers↗
Biomedical subjects
Bent Norgaard-Pedersen
Publications and source records attributed to Bent Norgaard-Pedersen.
Human fetal and tumor alpha-fetoproteins differ in conformationally dependent epitope variants expression.
Expression of two conformationally dependent epitopes (cdes) designated as cdeD and cde106 of human alpha-fetoprotein (hAFP) was studied in hAFP of fetal and tumor origin. This was done by immunoaffinity electrochromatography on nitrocellulose membrane and by ELISA. Using anti-cdeD and anti-cde106 monoclonal antibodies (MoAbs), the relationship between the cde-positive and cde-negative hAFP fractions was evaluated in 75 samples with the above techniques. It was shown that hAFP consists of cde-positive and -negative variants irrespective of its tissue origin. In all the tested AFP samples, cde-negative variants were found to be predominant, while certain quantitative differences in the content of cde-positive variants were observed. Thus, in the amniotic fluid hAFP (irrespective of normal or pathological fetal development), the level of the cde-positive molecules was higher than in hAFP of other origin (cord blood serum, patients' sera with hepatocellular carcinoma, germ cell tumors, and the other hAFP-positive tumor cases). In all the tested samples, cdeD- and cde106-positive variants were revealed practically in parallel with each other.
Amniotic Fluid↗
Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
BACKGROUND: The p53 gene is frequently mutated in various human tumours. In addition, single nucleotide polymorphisms are often observed in exons and introns of the p53 gene in normal tissues and tumours. MATERIALS AND METHODS: A total of 210 blood and tissue samples from 182 ovarian cancers (OC) and 28 ovarian borderline tumours, in addition to blood samples from 72 healthy women, were analysed. The used analyses were PCR and SSCP. The distinguishable SSCP patterns were confirmed by DNA sequencing. RESULTS: A polymorphism located at position 38 in intron 2 of the p53 gene was studied in blood and tumour tissues from Danish ovarian tumour patients and in blood from controls. Significant differences were found between the distributions of the genotypes in blood samples compared to the corresponding tissue samples (p = 0.0002). A tendency towards a significant difference in survival was observed between OC stage II patients with a shift from one genotype in the blood to another genotype in the tissue and patients with no shift (p = 0.05). In multivariate COX regression analysis restricted to stage III OC patients, the only independent factors found were shift, serum-tetranectin and age. CONCLUSION: A shift from one p53 intron 2 genotype in the blood to another genotype in the tissue may be a prognostic factor in ovarian cancer patients.
Adult↗